Coherus

J.P. Morgan Annual Healthcare Conference

Denny Lanfear, Chief Executive Officer

January 10, 2024

Forward Looking Statements

Forward Looking Statements - Except for the historical information discussed today and contained herein, the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding partnerships and collaborations that may maximize value; expectations for the launch timing for UDENYCA OBI; our expectations for share, opportunity, demand and payer coverage all increasing for UDENYCA; market opportunity projections for LOQTORZI; our ability to reach the full NPC patient population with LOQTORZI; our expectations about HCPs who represent potential targets for LOQTORZI promotion; our expectations for the efficacy of casdozokitug or our other product candidates; our expectations that combinations with our internal pipeline and external collaborators will unlock value; expectations about the timing or ability to achieve future catalysts with our pipeline product candidates, including filing an IND for CHS-1000 and obtaining phase 1 data for CHS-114; and our ability to realize financial contributions and revenues from CIMERLI and YUSIMRY in 2024 and future years. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties caused by our transition from a biosimilar focused company to an innovative immuno-oncology franchise funded by sales from FDA-approved therapeutics; the risks and uncertainties inherent with clinical research and commercialization; the risks and uncertainties of the clinical development and regulatory approval process, including (but not limited to) the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions; risks and uncertainties in executing collaboration agreements and other joint ventures, including particular risks of working with international partners; and the risks and uncertainties of litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, filed with the Securities and Exchange Commission on November 6, 2023, including the section therein captioned “Risk Factors,” and in other documents Coherus files with the Securities and Exchange Commission. UDENYCA®, YUSIMRY™, CIMERLI® and LOQTORZI™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this presentation are, to the knowledge of Coherus, the property of their respective owners.

Agenda

Company Summary

Core Oncology Business

R&D Outlook

Non-Core Products

Concluding Remarks

A Revenue Stage Fully Integrated Oncology Company

A Robust Portfolio of Oncology Products

LOQTORZI™ (toripalimab-tpzi) injection

UDENYCA® pegfilgrastim-cbqv

Combinations with LOQTORZI to Enhance Antitumor Immune Response



Delivering on Long Term Strategy

Launch Products, Grow Revenues, Manage Spend

Proven Execution

5 FDA Approvals
4 Product Launches

- UDENYCA OBI approval Q4 2023
- LOQTORZI approval and launch
- UDENYCA Autoinjector approval and launch
- CIMERLI approval and launch
- YUSIMRY approval and launch

Long Term Revenue Drivers

Revenue Growth from Commercial Portfolio

LOQTORZI™ (toripalimab-tpzi) injection

UDENYCA® pegfilgrastim-cbqv

Non-Core

CIMERLI™ (ranibizumab-eqrn) injection

YUSIMRY™ (adalimumab-aqvh) Injection

Financial Discipline

Strengthening Balance Sheet

- Portfolio prioritization to optimize R&D spend
- SG&A tight expense management
- Align capital structure with strategy
- Pursuing partnerships and collaborations to maximize value

2023 Revenue Growth

Quarter over quarter sales growth from Q1 through Q4

- **2023 Net Revenues** ($255 - $260 million) achieved upper end of guidance range
  - Q4 revenues >$90M
- **CIMERLI** – Quarter-over-quarter revenue growth after Q-Code April 2023
- **UDENYCA** – Quarter-over-quarter net revenue growth
  - Strong ASP to support Q1 2024 OBI launch
  - Three presentations provide long term market share increase opportunity
- **LOQTORZI** –Distributors stocked, patients dosed, sales ramp initiated

The preliminary 2023 financial information presented here has not been reviewed by our auditor or audited and is subject to significant change. We have not completed our financial close process. The completed, audited Coherus Fourth Quarter and Full Year 2023 Financial Results are planned for release in March 2024

Agenda

- Company Summary
- Core Oncology Business
- R&D Outlook
- Non-Core Products
- Concluding Remarks

UDENYCA ONBODY Injector Approved December 2023

Proprietary State-of-the Art Delivery

Patient and Physician Informed R&D Bring Forward a Novel and Proprietary Injector



Translucent window with solid black **fill indicator** against a white background

High-quality, **well-tolerated adhesive**[1]

Metal medicine port and **green fill guide** support proper filling

Status light indicates if device is working properly

Innovative and Differentiating Device Features

Attribute	UDENYCA ONBODY[2,3]
Injection Time	**5 minutes**
Injection modality	Needle inserted at time of injection and **remains inserted for only 5 minutes**
Needle retraction	**Automatic retraction** of needle after delivery
Fill indicator	**Black indicator** moves against a **white background**
Adhesive	Large surface area with **well-tolerated adhesive**[1]

References:
1. Data on file. Coherus BioSciences, Inc.; 2023.
2. UDENYCA ONBODY HCP Instructions for Use.
3. UDENYCA Prescribing Information.

Comprehensive Franchise Built for Profitable Growth

Innovation Provides the Total Solution

UDENYCA® pegfilgrastim-cbqv

Total Solution Reaches More Patients, Drives Long Term Share Growth

Prefilled Syringe Patient

- Prefers next day visit with oncologists
- Likes the confidence of in-office administration

Autoinjector Patient

- Desires control over injection process
- Comfortable with self-injections

On-Body Injector Patient

- Unable to come back to the office next day
- Prefer “set it and forget it”

The Only Pegfilgrastim Brand with Three Presentation Options

UDENYCA Core Business Is Strong and Growing

Executing a Strategy to Maximize Revenue and Profitability

2023: Delivered the Growth



2024: Continued Growth Drivers

- **Base Business PFS Share >17%**, +6 share points gained in 2023
- **OBI Approval & launch** unlocks significant opportunity
- **Autoinjector demand increasing**
- **Payer coverage nearly doubles** vs. 2023

Source: IQVIA National Sales Perspective; 4Q23 R4W from week ending 12/1/23 to 12/22/23

LOQTORZI: Establishing a New Standard of Care as the First and Only FDA-Approved Treatment for Nasopharyngeal Carcinoma (NPC) in All Lines of Therapy

~$200M Market Opportunity

Leveraging existing commercial oncology footprint to reach the full NPC patient population in the U.S.

Only I-O treatment with Preferred Category 1 designation under NCCN
in combination with gemcitabine and cisplatin

Only Preferred NCCN regimen in 2nd Line treatment and later
Strongly supportive patient and physician community

2,000 NPC treated patients
Estimated annual U.S. patient population

"LOQTORZI is a new treatment option that has demonstrated the ability to significantly improve PFS and OS and should quickly emerge as the new standard of care when used in combination with chemotherapy."

Jong Chul Park, M.D.
Assistant Professor, Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center

Focused on Driving Rapid LOQTORZI Adoption

Identifying Patients and Targeting Healthcare Providers

Targeted HCP Promotion



HCP Segmentation

PD-1 User (50%)

- Early Adopter (~30%)
- Non-early Adopter (~20%)

Chemo User (50%)

Tools to Identify Patients*



IQVIA NPC Predictive Alerts



EHR Instruction Tool

- Claims Source: IQVIA Claims data through 4/22/2023, R1Y totals
- NPC Value weightings

* Examples of several tools being implemented

Engaging and Educating the NPC Patient Community

>2,100 NPC Patients & Caregivers Enrolled in our Community

Branded Patient Campaign

Campaign Education Flow

YOUR NPC FACTS

Primes With NPC Disease State Education

LOQTORZI™ (toripalimab-tpzi)injection

Steady Cadence of Branded Information to Request by Name

Agenda

- Company Summary
- Core Oncology Business
- R&D Outlook
- Non-Core Products
- Concluding Remarks

LOQTORZI Combinations with Tumor Microenvironment Agents Aim to Extend Cancer Patients Survival

First-in-Class and Competitively Positioned Assets with Supporting Clinical Data

Extending Survival



Coherus I-O Pipeline: Tumor Microenvironment focus

		Pre Clinical	Phase 1	Phase 2	Pivotal Clinical Trials	FDA Approved
LOQTORZI	PD-1					
Casdozokitug	IL-27					
CHS-114	CCR8					
CHS-1000	ILT4					

Source: “Immune Checkpoint Blockade in Cancer Therapy”; Allison, James; Nobel Lecture (December 2018)

PD-1 Inhibitor + TME Targeting Agents to Overcome PD-1 Resistance

- Relieving T/NK cell exhaustion (toripalimab-tpzi; casdozokitug)
- Targeting/reprogramming major resistance mechanisms (casdozokitug, CHS-114, CHS-1000)

LOQTORZI

Anti-PD-1



FDA approved label expansion through combinations

Casdozo

Anti-IL-27



First and only clinical stage

CHS-114

Anti-CCR8

Highly selective and potent

CHS-1000

Anti-ILT4



Promising approach for overcoming PD-1 resistance

IL-27 Mechanism of Tumor Immune Suppression



IL-27 upregulates checkpoint receptors





Chihara et al, Nature 558, 2018
DeLong et al, Immunohorizons 3, 2019

IL-27 downregulates pro-inflammatory cytokines





Chihara et al, Nature 558, 2018
DeLong et al, Immunohorizons 3, 2019

IL-27 constrains NK cell immunosurveillance





Aghayev et al, Cancer Discov, 12, 2022

Casdozokitug has Demonstrated Monotherapy Activity in Lung Cancer



- 2 confirmed PRs in PD-L1 negative or low, squamous NSCLC and 1 durable disease stabilization in adenocarcinoma; all 3 previously treated with PD-(L)1 antibodies
- 22% ORR in squamous subset (n=2/9)
- Clinical demonstration of PoM – immune activation in cancer patients
- Phase 1b/2 combination trial with LOQTORZI, which has proven NSCLC efficacy, is progressing

Marron, T., et al., 2023 ESMO Immuno-Oncology Congress, Poster #122P

Casdozo Combination Activity in First-Line Liver Cancer

Early and Encouraging Data

Casdozokitug/Atezolizumab/Bevacizumab in Hepatocellular Carcinoma (HCC)

Best Percent Change from Baseline in Sum of Target Lesions (n=24)



- Early data snapshot, with ~50% of patients with ≤ 1 on-study imaging assessment (30 patients treated)
- 27% ORR to date in response evaluable set
- Unique first line liver cancer opportunities with toripalimab

More mature data set being presented at 2024 ASCO GI Next Week!!

Data cut as of 14 Apr 2023, subject to change

Combinations with Internal Pipeline and External Collaborators Will Unlock Value and Expand Indications



Combined I-O Pipeline with 2024 Catalysts

Innovative Immuno-Oncology Pipeline

Agent	Target	Proposed Indication	Preclinical	Phase 1	Phase 2	Pivotal Clinical Trials	Approval	Near-Term Catalysts
LOQTORZI	PD-1	**Nasopharyngeal Carcinoma** (1L combo with chemo) **Nasopharyngeal Carcinoma** (2L/3L monotherapy)						**U.S. Launch in NPC: External Research Collaborations** Q1 2024
Casdozokitug	IL-27	**Hepatocellular Carcinoma** **Non-Small Cell Lung Cancer**						**HCC Triplet Combo Data – Q1 24** **NSCLC Monotherapy Data** Q4 23-ongoing
CHS-114	CCR8	**Solid Tumors including Head & Neck Cancer**						**CHS-114 Phase 1 Data –** H1 24
CHS-1000	ILT4	**Solid Tumors** (in combination with toripalimab)						**IND Filing** H1 24

TIGIT asset discontinued

Agenda

- Company Summary
- Core Oncology Business
- R&D Outlook
- Non-Core Products
- Concluding Remarks

CIMERLI and YUSIMRY

Non-Core Products Provide Additional Value Contribution in 2024

~ $125M Cumulative Annual Net Revenue thru Q4 2023[1]

29% market share in Q3 among ranibizumab class; 38% R4W share thru 12/22/23[2]

~190,000 Doses Shipped Since Launch[3]

Efficacy and safety profile delivering on its promise

Innovators of Low WAC Strategy

Launched at 85% discount to branded HUMIRA® & positions for IRA implementation in ‘25

Partnership with Mark Cuban Cost Plus Drug Company

Serving customers and patients desiring affordable, transparent price for adalimumab

1. The preliminary 2023 financial information presented here has not been reviewed by our auditor or audited and is subject to significant change. We have not completed our financial close process. The completed, audited Coherus Fourth Quarter and Full Year 2023 Financial Results are planned for release in March 2024;
2. IQVIA WSP & NSP Q1-Q3 3023; 3. Coherus demand data through Dec 29, 2023

Agenda

- Company Summary
- Core Oncology Business
- R&D Outlook
- Non-Core Products
- Concluding Remarks

Delivering on Long Term Strategy

Launch Products, Grow Revenues, Manage Spend

Proven Execution

5 FDA Approvals
4 Product Launches

- UDENYCA OBI approval Q4 2023
- LOQTORZI approval and launch
- UDENYCA Autoinjector approval and launch
- CIMERLI approval and launch
- YUSIMRY approval and launch

Long Term Revenue Drivers

Revenue Growth from Commercial Portfolio

LOQTORZI™ (toripalimab-tpzi) injection

UDENYCA® pegfilgrastim-cbqv

Non-Core

CIMERLI™ (ranibizumab-eqrn) injection

YUSIMRY™ (adalimumab-aqvh) Injection

Financial Discipline

Strengthening Balance Sheet

- Portfolio prioritization to optimize R&D spend
- SG&A tight expense management
- Align capital structure with strategy
- Pursuing partnerships and collaborations to maximize value

Coherus

Thank You

www.coherus.com